Posizioni attive di Douglas Hanahan
Società | Posizione | Inizio | Fine |
---|---|---|---|
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | Direttore/Membro del Consiglio | - | - |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Direttore/Membro del Consiglio | - | - |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Direttore/Membro del Consiglio | - | - |
Fondatore | - | - |
Storia della carriera di Douglas Hanahan
Statistiche
Distribuzione geografica
Svizzera | 3 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 3 |
Founder | 1 |
Settori
Health Technology | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | Commercial Services |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Health Technology |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Health Technology |
- Borsa valori
- Insiders
- Douglas Hanahan
- Esperienza